REFERENCES
- Tomaszewski, J., and Rumore, M. M. 1994. Stereoisomeric drugs: FDA’s policy statement and the impact on drug development. Drug Develop. Ind. Pharm. 20(2):119–139.
- Stoschitzky, K., Linder, W., Egginger, C, Brunner, F., Obermayer-Pietsch, B., Passath, A., and Klein, W. 1992. Racemic (R, S)-propranolol versus half-dosed optically pure S)-propranolol in humans at steady state: Hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels. Clin. Pharmacol. Ther. 51:445.
- Jamali, F., and Wechter, W. J. 1992. From controversy to resolution: Bioequivalence of racemic drugs-abstracts. J. Clin. Pharmacol. 32:955–962.
- Nerurkar, S. G., Dighe, S. V., and Williams, R. L. 1992. Bioequivalence of racemic drugs. J. Clin. Pharmacol. 32:935–943.
- Adeyeye, C. M., and Chen, F. 1997. Stereoselective disposition of suspensions of conventional and wax matrix sustained release ibuprofen microspheres in rats. Pharm. Res. 14(12):1810–1815.
- Sattari, S., and Jamali, F. 1994. Evidence of absorption rate dependency of ibuprofen inversion in rats. Chirality 6:435–439.
- Janjikhel, R. K., and Adeyeye, C. M. 1997. Stereospecific formulation and characterization of sustained release ibuprofen microspheres. J. Microen-capsul. 14(4):409–426.
- Anon, 1993. In vitro-in vivo correlations. Pharmacop. Forum 19(3):5374–5379.
- Skelley, J. P., Amidon, G. L., Barr, W. H., Benet, L. Z., Carter, J. E., Robin-son, J. R., Shah, V. P., and Yacobi, A. 1990. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm. Res. 7(9):975–982.
- Adeyeye, C. M., and Price, J. C. 1991. Development and evaluation of sustained release ibuprofen wax microspheres. I. Effect of formulation variables on physical characteristics. Pharm. Res. 8(11): 1377–1383.
- Adeyeye, C. M., and Price, J. C. 1994. Development and evaluation of sustained release ibuprofen wax microspheres. II. In vitro dissolution studies. Pharm. Res. 11 (4):575-579.
- Wright, M. R., Sattari, S., Brocks, D. R., and Jamali, F. 1992. Improved HPLC assay method for the enantiomers of ibuprofen. J. Chromatogr. 583:259–265.
- Lemko, C. H., Caille, G., and Foster, R. T. 1993. Stereospecific high-performance liquid chromatography assay of ibuprofen: Improved sensitivity and sample processing efficiency. J. Chromatogr. 619:330–335.
- Gillespie, W. R. PCDCON: Deconvolution for pharmacokinetic applications, version 1.1.
- Sattari, S., and Jamali, F. 1994. Evidence of absorption rate dependency of ibuprofen inversion in rats. Chirality 6:435–439.
- Wilson, C. G., Washington, N., Greaves, J. L., Jamali, F., Rees, J. A., Sempik, A. K., and Lampard, J. F 1989. Bimodal absorption of ibuprofen in a sustained release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake. Int. J. Pharmaceutics 50:155–161.
- Washington, C, Washington, N., and Wilson, C. 1990. Sustained release dosage forms and the gastrointestinal tract. In Pharmacokinetic Modeling using Stella on the AppleTM MacintoshTM,91-111. New York: Ellis Horwood.